Telecommunication Technology-based Online Survey
New Challenges for the Population on the Path to Achieving Active Longevity: an Online Survey of Respondents Using Telecommunication Technologies
Tomsk National Research Medical Center of the Russian Academy of Sciences
2,000 participants
Dec 2, 2022
OBSERVATIONAL
Conditions
Summary
The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.
Eligibility
Inclusion Criteria3
- age of 18 years and older
- signing the informed concent form online
- completion of the entire questionnaire
Exclusion Criteria2
- age under 18 years
- refuse to sign the informed concent form
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06159699